Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Kenvue (KUVE) has named Kirk Perry, a current director, as its interim CEO, effective immediately. Concurrently, Thibaut ...

Kenvue names interim CEO, begins strategic review to simplify operations and considers divesting smaller beauty brands amid ...

The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

Despite the earnings beat, Kenvue (NYSE:KVUE)’s stock dipped 0.9% following the release, suggesting a muted market reaction to the results. For the full year 2025, Kenvue now expects net sales ...

Kenvue says that CEO Thibaut Mongon is departing as the maker of Listerine and Band-Aid brands continues with a strategic ...

Q1 revenue hit $3.74 billion vs. $3.68 billion consensus; sales down 3.9% YoY on lower volume and currency impact. Adjusted operating margin fell to 19.8% from 22.0% YoY 3 Summer "Power Patterns ...

Kenvue (KVUE) delivered earnings and revenue surprises of 14.29% and 1.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- Kenvue Inc. reported second-quarter earnings that surpassed analyst estimates, while updating its full-year 2025 guidance to account for tariffs and currency headwinds. The company’s ...

Investing.com -- Kenvue Inc. reported second-quarter earnings that surpassed analyst estimates, while updating its full-year 2025 guidance to account for tariffs and currency headwinds. The company’s ...